Open AccessHeparan Sulfate and Chondroitin Sulfate Glycosaminoglycans Are Targeted by Bleomycin in Cancer Cells
Author(s) -
Xiulian Li,
Ying Lan,
Yong He,
Yong Liu,
Heng Luo,
Haibo Yu,
Ning Song,
Sumei Ren,
Tianwei Liu,
Cui Hao,
Yunliang Guo,
Lijuan Zhang
Publication year - 2017
Publication title -
cellular physiology and biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.486
H-Index - 87
eISSN - 1421-9778
pISSN - 1015-8987
DOI - 10.1159/000481763
Subject(s) - heparan sulfate , glycosaminoglycan , bleomycin , chondroitin sulfate , chondroitin , heparanase , sulfate , chemistry , perlecan , heparin , sulfation , cancer research , biochemistry , microbiology and biotechnology , biophysics , medicine , biology , chemotherapy , organic chemistry
Bleomycin is a clinically used anti-cancer drug that produces DNA breaks once inside of cells. However, bleomycin is a positively charged molecule and cannot get inside of cells by free diffusion. We previously reported that the cell surface negatively charged glycosaminoglycans (GAGs) may be involved in the cellular uptake of bleomycin. We also observed that a class of positively charged small molecules has Golgi localization once inside of the cells. We therefore hypothesized that bleomycin might perturb Golgi-operated GAG biosynthesis.